Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05192603
Other study ID # IBS-2021
Secondary ID
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date March 1, 2022
Est. completion date March 31, 2029

Study information

Verified date November 2023
Source Region Skane
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the present study is to compare the efficiency of low FODMAP and SSRD to reduce symptoms in IBS, and to study the mechanisms and consequences of the two diets.


Description:

The investigator will perform a study on 200 subjects with verified irritable bowel syndrome (IBS). Participants will be recruited from the clinic of Gastroenterology or Internal medicine as well as primary health care centers. At the start of the study, participants will complete protocols concerning Rom IV criteria (to validate that the IBS criteria are ful-filled) as well as IBS symptom rating scales irritable bowel syndrome-symptoms severity scores (IBS-SSS) and visual analog scale for irritable bowel syndrome (VAS-IBS). The Item Health Survey 1.0 (distributed by RAND), RAND-36, includes the same items as those in the Short-Form Health Survey (SF-36), and evaluates the quality of Life. SCOFF is a brief questionnaire that asks the five questions about eating disturbances (Do you make yourself Sick because you feel uncomfortably full? Do you worry you have lost Control over how much you eat? Have you recently lost more than One stone in a 3 month period? Do you believe yourself to be Fat when others say you are too thin? Would you say that Food dominates your life?). Participants will be examined by an investigator who will complete protocols of clinical data. Blood and fecal samples will be collected by the investigator. Study participants will thereafter be randomized to receive either low FODMAP (Fermentable, Oligo-, Di-, Mono-saccharides And Polyols) diet (n=100), or a SSRD diet (starch ans sucrose-reduced diet) (n=100). After 4 weeks of dietary intervention, there will be a follow-up where blood and fecal samples are once again collected. At this point in time, participants will also fill in IBS symptom rating scales again. The participants are then free to eat whatever they want to, and another 5 months later, they will be examined again, the same protocols will be completed, and blood and fecal samples are collected. The investigator will use samples from baseline, 4 weeks and 6 months, for genetic/epigenetic (including genomic-wide association studies), metabolomics, proteomics, nutritional data, gut microbiota, and inflammatory parameter analyses. Statistics The investigator will use Mann-Whitney U-test and Wilcoxon test to study differences in the above-mentioned parameters between the two treatment groups, as well as before and after dietary intervention, respectively. For analyses of genetic/epigenetics, metabolomics, proteomics, and microbiota, the investigator will use bioinformatics and biostatistics.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 200
Est. completion date March 31, 2029
Est. primary completion date March 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Verified IBS according to Rom IV criteria. Exclusion Criteria: - Serious mental disease - Serious somatic disease - Abuse - Inability to understand the Swedish language - Already on a diet

Study Design


Intervention

Dietary Supplement:
low FODMAP or SSRD
The participants are given oral and written information about each diet. No food is delivered from the investigator to the participant

Locations

Country Name City State
Sweden Deartment of INternal Medicine Malmö

Sponsors (1)

Lead Sponsor Collaborator
Region Skane

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficiency on bowel and extra-intestinal symptoms To assess bowel symptoms and extra-intestinal symptoms after the dietary interventions by evaluation of irritable bowel syndrome-symptom severity score (IBS-SSS). This questionnaire contains VAS scales ranging from 0-100 where a higher score means worse symptoms. 4 weeks dietary intervention
Primary Efficiency on bowel and extra-intestinal symptoms To assess bowel symptoms and extra-intestinal symptoms after the dietary interventions by evaluation of IBS-SSS. This questionnaire contains VAS scales ranging from 0-100 where a higher score means worse symptoms. A follow-up 5 months after the end of the intervention
Primary Efficiency on bowel symptoms To assess bowel symptoms after the dietary interventions by evaluation of visual analog scale for irritable bowel syndrome (VAS-IBS). This questionnaire contains VAS scales ranging from 0-100 where a higher score means worse symptoms. 4 weeks dietary intervention
Primary Efficiency on bowel symptoms To assess bowel symptoms after the dietary interventions by evaluation of visual analog scale for irritable bowel syndrome (VAS-IBS). This questionnaire contains VAS scales ranging from 0-100 where a higher score means worse symptoms. A follow-up 5 months after the end of the intervention
Secondary Effects on plasminogen activator inhibitor-1 (PAI-1) The investigator will analyze plasminogen activator inhibitor-1 (PAI-1) by enzyme-linked immunosorbent assay (ELISA) to see and compare the effects of the two different diets. 4 weeks dietary intervention, with a follow-up after another 5 months
Secondary Effects on C-peptide The investigator will analyze C-peptide by enzyme-linked immunosorbent assay (ELISA) to see and compare the effects of the two different diets. 4 weeks dietary intervention, with a follow-up after another 5 months
Secondary Effects on insulin The investigator will analyze insulin by enzyme-linked immunosorbent assay (ELISA) to see and compare the effects of the two different diets. 4 weeks dietary intervention, with a follow-up after another 5 months
Secondary Effects on leptin The investigator will analyze leptin by enzyme-linked immunosorbent assay (ELISA) to see and compare the effects of the two different diets. 4 weeks dietary intervention, with a follow-up after another 5 months
Secondary Effects on gastric inhibitory peptide (GIP) The investigator will analyze GIP by enzyme-linked immunosorbent assay (ELISA) to see and compare the effects of the two different diets. 4 weeks dietary intervention, with a follow-up after another 5 months
Secondary Effects on visfatin The investigator will analyze visfatin by mesoscale to see and compare the effects of the two different diets. 4 weeks dietary intervention, with a follow-up after another 5 months
Secondary Effects on ghrelin The investigator will analyze ghrelin by mesoscale to see and compare the effects of the two different diets. 4 weeks dietary intervention, with a follow-up after another 5 months
Secondary Effects on gut microbiota by whole genome sequencing of feces The investigator will analyze fecal microbiota by whole genome sequencing to see and compare the effects of the two different diets 4 weeks dietary intervention, with a follow-up after another 5 months
Secondary Effects on microRNA The investigator will analyze microRNA to see and compare the effects of the two different diets 4 weeks dietary intervention, with a follow-up after another 5 months
Secondary Effects on DNA methylation The investigator will analyze DNA methylation to see and compare the effects of the two different diets 4 weeks dietary intervention, with a follow-up after another 5 months
Secondary Effects depending on genetics The investigator will analyze sucrase-isomaltase (SI) genes to see if the genetic profile hais of importance for the clinical effect of the two diets 4 weeks dietary intervention, with a follow-up after another 5 months
Secondary Effects on vitamin A The investigator will analyze values of vitamin A in blood before and after the study to compare the effects on the nutritional status by the two diets. 4 weeks dietary intervention, with a follow-up after another 5 months
Secondary Effects on vitamin B The investigator will analyze values of vitamin B in blood before and after the study to compare the effects on the nutritional status by the two diets. 4 weeks dietary intervention, with a follow-up after another 5 months
Secondary Effects on vitamin C The investigator will analyze values of vitamin C in blood before and after the study to compare the effects on the nutritional status by the two diets. 4 weeks dietary intervention, with a follow-up after another 5 months
Secondary Effects on vitamin D The investigator will analyze values of vitamin D in blood before and after the study to compare the effects on the nutritional status by the two diets. 4 weeks dietary intervention, with a follow-up after another 5 months
Secondary Effects on phosphorous The investigator will analyze values of phosphorous in blood before and after the study to compare the effects on the nutritional status by the two diets. 4 weeks dietary intervention, with a follow-up after another 5 months
Secondary Effects on zinc The investigator will analyze values of zinc in blood before and after the study to compare the effects on the nutritional status by the two diets. 4 weeks dietary intervention, with a follow-up after another 5 months
Secondary Effects on magnesium The investigator will analyze values of magnesium in blood before and after the study to compare the effects on the nutritional status by the two diets. 4 weeks dietary intervention, with a follow-up after another 5 months
Secondary Effects on albumin The investigator will analyze values of albumin in blood before and after the study to compare the effects on the nutritional status by the two diets. 4 weeks dietary intervention, with a follow-up after another 5 months
Secondary Effects on metabolomics and proteomics The investigator will analyze metabolomics and proteomics in blood to see and compare the effects of the two different diets 4 weeks dietary intervention, with a follow-up after another 5 months
Secondary Effects on quality of life by RAND-36 (comprehensive short-form generic profile for health-related quality of life (HRQoL)) The investigator will analyze how the two different diets influence quality of life, measured by RAND-36, to compare the effects of the two different diets. RAND-36 is comprised of 36 items on 5-point Likert scale, the higher score the better quality of life, that assess eight health concepts: physical functioning, role limitations caused by physical health problems, role limitations caused by emotional problems, social functioning, emotional well-being, energy/fatigue, pain, and general health perceptions. 4 weeks dietary intervention, with a follow-up after another 5 months
Secondary Effects on eating disturbances The investigator will analyze how the two different diets influence eating disturbances measured by SCOFF, to compare the effects of the two different diets. SCOFF contains 5 questions answered by "yes" or "no": 1) Do you make yourself Sick because you feel uncomfortably full?, 2) Do you worry that you have lost Control over how much you eat?, 3)Have you recently lost more than One stone (14 lb) in a 3-month period?, 4)Do you believe yourself to be Fat when others say you are too thin?, and 5) Would you say that Food dominates your life? 4 weeks dietary intervention, with a follow-up after another 5 months
Secondary Effects on healthcare consumption The investigator will analyze how the two different diets influence healthcare consumption by asking the participants about how many times they have visited a Healthcare giver before, during and after the study, to compare the effects of the two different diets 4 weeks dietary intervention, with a follow-up after another 5 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05118243 - Innovative Tools to Produce Legume-based Foods for Increased Consumer Acceptance N/A
Completed NCT04422327 - The Impact of a Combination of Bifidobacterium Longum 35624® and 1714™ Strains in Adults With Irritable Bowel Syndrome Phase 1/Phase 2
Recruiting NCT05178017 - Lifestyle Eating and Performance (LEAP) Program for the Treatment of Irritable Bowel Syndrome (IBS) N/A
Completed NCT05197413 - Study to Evaluate the Efficacy of Arrae's Bloat & Calm Alchemy Capsules to Reduce Bloating, Heartburn and Gas, and Alleviate the Intensity of IBS Symptoms N/A
Completed NCT04905524 - Activity Changes in Irritable Bowel Syndrome (IBS), Anxiety, and Depression Following the Use of Viome Precision Nutrition Program (VPNP) N/A
Recruiting NCT06297785 - Online, Gut-directed Hypnotherapy for Patients With Irritable Bowel Syndrome (IBS) N/A
Recruiting NCT05874830 - The Optimal Route of Fecal Microbiota Transplantation for Irritable Bowel Syndrome N/A
Active, not recruiting NCT04723056 - Zemedy Application for Irritable Bowel Syndrome N/A
Recruiting NCT05565612 - Clinical Trial to Evaluate the Effect of a Probiotic Mixture on Signs and Symptoms of Irritable Bowel Syndrome N/A
Recruiting NCT03131414 - The IMAGINE-SPOR CIHR Chronic Disease Network
Completed NCT03333291 - Fecal Transplantation in Patients With IBS N/A
Completed NCT03449628 - L. Casei DG® in Patients With Irritable Bowel Syndrome. N/A
Recruiting NCT06215222 - Capsule Microbiota Sampling in IBS/Functional Gastrointestinal Disease
Completed NCT05016596 - Postprandial Lipids in IBS and Nutritional Treatment N/A
Recruiting NCT04760353 - The Effect of a Probiotic Mixture in Obese Patients With Irritable Bowel Syndrome N/A
Recruiting NCT04217733 - Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome Phase 3
Completed NCT03178877 - The Prevalence of Irritable Bowel Syndrome Using Rome IV Criteria in Medical Student and The Related Factors N/A
Recruiting NCT05990764 - Effects of a Combination of Polyphenol-rich Extracts, Prebiotics, and Hydrolyzed Fiber on the Quality of Life of Patients With Irritable Bowel Syndrome (IBS) N/A
Completed NCT03948854 - Implementing a Low FODMAP Diet in Irritable Bowel Syndrome Patients N/A
Completed NCT04898257 - Effect of Lactibiane Tolerance® to Treat Leaky Gut in Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)Patients N/A